Evidence map›Paper›PMID 34630088›Full record

ArticleFrontiers in pharmacology2021

Mefunidone Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice.

Yuanyuan Han, Mao Jiang, Rongling He, Xin Lv, Xiaohua Liao, Yijun He, Fan Zhang, Lingzhi Long, Guoliang Jiang, Zhangzhe Peng and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Systematic Analysis Strategy Based on Network Pharmacology to Investigate the Potential Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Yuanyuan HanDepartment of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
Mao JiangDepartment of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
Rongling HeDepartment of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
Xin LvHunan Key Laboratory of Organ Fibrosis, Changsha, China.
Xiaohua LiaoHunan Key Laboratory of Organ Fibrosis, Changsha, China.
Yijun HeDepartment of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
Fan ZhangDepartment of Anesthesiology, Xiangya Hospital of Central South University, Changsha, China.
Lingzhi LongDepartment of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
Guoliang JiangDepartment of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
Zhangzhe PengHunan Key Laboratory of Organ Fibrosis, Changsha, China.
Lijian TaoHunan Key Laboratory of Organ Fibrosis, Changsha, China.
Gaoyun HuDepartment of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Jie MengDepartment of Pulmonary and Critical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China.
Xiangya Hospital Central South University · CNCentral South University · CNThird Xiangya Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is one of the most common and devastating interstitial lung diseases with poor prognosis. Currently, few effective drugs are available for IPF. Hence, we sought to explore the role of mefunidone (MFD), a newly synthesized drug developed by our team, in lung fibrosis. In this study, MFD was found to attenuate bleomycin (BLM) -induced lung fibrosis and inflammation in mice according to Ashcroft and alveolitis scoring. The protein contents and total cell counts in bronchoalveolar lavage fluids of BLM-treated mice were also lowered by MFD. Moreover, the elevation of TGF-β/Smad2 and phosphorylation of MAPK pathways was repressed by MFD. Additionally, MFD attenuated the swelling and vacuolization of mitochondria, lowered the ratio of apoptotic cells, restored the mitochondrial membrane potential, and reversed the expression of cleaved-caspase 3, Bcl-2 and Bax. Meanwhile, the level of epithelial marker, E-cadherin, was restored by MFD, while the levels of mesenchymal markers such as Snail and vimentin were down-regulated by MFD. Besides, MFD inhibited the expression of fibronectin and α-smooth muscle actin in TGF-β treated normal human lung fibroblasts. Thus, our findings suggested that MFD could ameliorate lung fibrosis, cell apoptosis and EMT potentially

Indexed as

apoptosisepithelial-mesenchymal transitionmefunidonepulmonary fibrosisTGF-β

Identifiers

PMID34630088
PMCPMC8499630
OpenAlexW3202980917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.